ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2122

Mechanical Back Pain Demonstrates Better Response To Celecoxib Than Acetaminophen Despite Lack Of MRI-Defined Inflammatory Changes In The Spine

Dinny Wallis1, Finbar (Barry) D. O'Shea2, David Salonen3, Nigil Haroon1, Ammepa Anton4, Laura A. Passalent5, Rebecca Morton6, Christopher Hawke7, Joan Blair7 and Robert D. Inman7, 1Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 2Rheumatology Dept, St James's Hospital, Dublin, Ireland, 3Department of Medical Imaging, University Health Network, Toronto, ON, Canada, 4Rheumatology, University Health Network, Toronto, ON, Canada, 5Allied Health, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 6Allied Health/Rheumatology, University Health Network- Toronto Western Hospital, Toronto, ON, Canada, 7Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Back pain and nonsteroidal antiinflammatory drugs (NSAIDs)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Orthopedics, Low Back Pain and Rehabilitation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Chronic back pain affects a significant proportion of the population.  MRI-defined inflammatory lesions have been used to differentiate between axial spondyloarthritis and mechanical back pain, but the frequency of inflammatory lesions in mechanical back pain has not been ascertained.  The efficacy of celecoxib in chronic, mechanical back pain and its effects on MRI inflammatory lesions have not been established. 

Methods:

A randomized, double-blind trial of celecoxib versus acetaminophen was conducted.  Fifty two patients (52% male, mean age 40y)with back pain for at least 3 months, a total back pain score ≥4/10 and without clinical or radiographic evidence of axial spondyloarthritis were randomized to celecoxib (200mg twice daily, n=25) or acetaminophen (500mg twice daily, n=27) for four weeks.  Total back pain, Oswestry Disability Index (ODI), nocturnal back pain, patient global assessment, morning stiffness, SF-36 mental component scale (MCS) and physical component scale (PCS), CRP, ESR and  Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index for inflammation of the sacroiliac joints (SIJ) and spine were measured at baseline and four weeks. 

Results:

A greater improvement was observed for celecoxib than for acetaminophen in total back pain (p=0.01), Oswestry Disability Index (p=0.003) and nocturnal back pain (p=0.01).  A trend was observed for greater improvement in patient global assessment with celecoxib (p=0.07).  The SPARCC MRI index was low at baseline and no change was seen over four weeks in either treatment group.  

Conclusion:

To our knowledge, this is the first study to demonstrate the efficacy of celecoxib compared with acetaminophen in chronic mechanical back pain.  MRI-defined inflammatory lesions were infrequent.  This finding has implications for the specificity of MRI-defined inflammatory lesions in axial spondyloarthritis. 

Table 1 Mean (SD) outcome measures from baseline to week 4

 

Acetaminophen (n=27)

Celecoxib (n=25)

P value for change in acetaminophen group versus change in celecoxib group

 

Baseline

Week 4

Mean of differences

P value

Baseline

Week 4

Mean of differences

P value

Total back pain (0-10)

5.8 (2.1)

5.1 (2.4)

-0.7 (1.8)

0.04

6.5 (1.7)

4.2 (2.6)

-2.3 (2.6)

0.0001

0.01

ODI (0-100)

19.2 (9.1)

17.6 (10.0)

-1.6 (4.3)

0.08

20.3 (8.2)

13.1 (8.9)

-7.1 (7.8)

0.0002

0.003

Nocturnal back pain (0-10)

4.5 (2.5)

4.8 (2.8)

0.3 (2.8)

0.59

4.7 (2.3)

3.0 (2.7)

-1.7 (2.6)

0.003

0.01

Patient global (0-10)

4.6 (2.1)

4.1 (2.4)

-0.5 (1.7)

0.16

4.7 (2.8)

3.0 (2.6)

-1.7 (2.8)

0.0066

0.07

Morning stiffness (0-10)

5.0 (2.7)

4.4 (2.5)

-0.6 (1.8)

0.12

3.0 (2.8)

2.5 (2.6)

0-.6 (2.9)

0.34

–

SF-36 MCS

47.4 (9.6)

47.7 (10.2)

0.3 (6.3)

0.82

44.7 (11.6)

47.7 (12.1)

3.0 (12.2)

0.24

–

SF-36 PCS

39.0 (11.4)

41.9 (11.1)

2.8 (5.7)

0.02

39.5 (9.2)

44.1 (9.2)

4.6 (6.6)

0.0025

0.38

CRP (mg/L)

2.7 (4.4)

2.2 (4.1)

-0.5 (3.8)

0.51

2.1 (2.2)

2.1 (2.4)

0.0

>0.99

–

ESR (mm/h)

8.4 (9.5)

6.7 (7.4)

-1.7 (3.6)

0.02

5.0 (4.0)

5.3 (4.0)

0.3 (3.9)

0.71

–

MRI index SIJ (0-72)

1.6 (2.3)

1.6 (2.3)

0.1 (0.4)

0.48

0.9 (1.6)

0.9 (1.4)

-0.02 (1.06)

0.93

–

MRI index spine(0-108)

4.3 (4.8)

4.8 (5.3)

0.49 (1.44)

0.09

6.03 (4.60)

5.63

-0.41 (1.04)

0.06

–

 


Disclosure:

D. Wallis,
None;

F. D. O’Shea,
None;

D. Salonen,
None;

N. Haroon,

Janssen Pharmaceutica Product, L.P.,

5,

Pfizer Inc,

5,

Amgen,

5,

Abbott Laboratories,

5;

A. Anton,
None;

L. A. Passalent,
None;

R. Morton,
None;

C. Hawke,
None;

J. Blair,
None;

R. D. Inman,

Abbott Immunology Pharmaceuticals,

5,

Janssen Pharmaceutica Product, L.P.,

5,

UCB,

5,

Pfizer Inc,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mechanical-back-pain-demonstrates-better-response-to-celecoxib-than-acetaminophen-despite-lack-of-mri-defined-inflammatory-changes-in-the-spine/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies